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A B S T R A C T
Co-infusion of ex-vivo generated megakaryocytic progenitors with hematopoietic stem/progenitor cells
(HSC/HPC) may contribute to a faster platelet recovery upon umbilical cord blood (UCB) transplantation.
A two stage protocol containing cell expansion and megakaryocyte (Mk) differentiation was established
using human UCB CD34+-enriched cells. The expansion stage used a pre-established protocol supported
by a human bone marrow mesenchymal stem cells (MSC) feeder layer and the differentiation stage
used TPO (100ng/mL) and IL-3 (10ng/mL).18% of culture-derivedMks had higher DNA content (>4N) and
were able to produce platelet-like particles. The proliferation extent of CD34+ cells obtained in the
expansion stage (FI-CD34+), rather than expansion duration, determined as a key parameter for efﬁcient
megakaryocytic differentiation. A maximum efﬁciency yield (EY) of 487.7Mks/input CD34+ cells was
obtained for a FI-CD34+ of 172.5, where a higher FI-CD34+ of 4213 resulted in a less efﬁcient
megakaryocytic differentiation (EY of 226.7 and 194.6 %CD41).
ã 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
1. Introduction
Allogeneic transplantation of CD34+-enriched cells fromhuman
umbilical cord blood (UCB) as a source of hematopoietic
stem/progenitor cells (HSC/HPC) is a potential therapy for treating
hemato-oncological diseases and other blood disorders in adult
patients [1,2]. However, a delayed platelet recovery is typically
associated to the transplantation of HSC/HPC from UCB, when
compared to adult sources (bone marrow (BM) and mobilized
peripheral blood (mPB)) [3]. Administration of ex-vivo generated
megakaryocytic progenitor cells and megakaryocytes (Mks) alone
or co-infusion with UCB HSC/HPC can be a promising strategy to
reduce the prolonged period of platelet recovery [4,5].
Mks are rare, large and polyploid myeloid cells, which reside
primary in the BM region adjacent to sinusoidal walls [6]. Platelet
biogenesis from Mks occurs through nuclear polyploidization,
cellular enlargement, cytoplasmic maturation and platelet release.
The production of Mks and platelets from different sources of cells
such as UCB, BM or mPB, as well as embryonic stem cells and
induced pluripotent stem cells has been studied over the last
decades [7]. In this context, different biological, chemical and
physical factors have been studied in order to establish an optimal
protocol to enhancemegakaryocytic differentiation fromprimitive
cell populations [8–11].
The main objective of this study was to test if an optimized
expansion stage followed by a megakaryocytic differentiation
stage would be an effective strategy to maximize Mk production
from UCB HSC/HPC. Speciﬁcally, we aimed at systematically
identifying a relation between proliferation extent of CD34+ cells
and effective megakaryocytic differentiation.
2. Material and methods
2.1. Cell culture
hUCB and hMSC samples were obtained from healthy donors
after maternal donor and donor informed consent, respectively.
CD34+-enriched cells from UCB were expanded using a previously
optimized protocol [12]. Brieﬂy, low density mononuclear cells
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(MNC) were separated from UCB (more than 9 UCB units from
individual donors) by Ficoll density gradient (1.077 g/mL; GE
Healthcare) and then enriched for CD34+ antigen by magnetic
activated cell sorting (MACS;Miltenyi Biotec). UCB CD34+-enriched
cells (ranging 70–90% CD34+ cells) were co-cultured (3.0103
cells/mL, 5mL) with BM mesenchymal stem cell (BM-MSC) feeder
layer. BM-MSC was previously cultured (totally from 3 different
individual donors, passage 3–6) using Dulbecco's modiﬁed
essential medium (DMEM; Gibco) plus 10% fetal bovine serum
(FBS; Gibco) until conﬂuence and then inactivated withmitomycin
C (0.5mg/mL, Sigma) to prevent cell overgrowth. Serum-free
QBSF-60 culture medium (Quality Biological Inc.) supplemented
with SCF (60ng/mL), Flt-3L (55ng/mL), TPO (50ng/mL) and b-FGF
(5ng/mL) (all from Peprotech) was used in the expansion stage
[12]. Expanded cells were differentiated toward Mk lineage at
density of 2.0105 cells/mL (totally in 1mL) in Iscove's modiﬁed
Dulbecco's medium (IMDM) supplemented with 10% FBS, 1%
penicillin–streptomycin and 0.1% Fungizone (all from Gibco). The
effect of different concentrations and combinations of IL-3
(10ng/mL) and TPO (30, 50 and 100ng/mL; both from Peprotech)
were evaluated. At days 3, 5 and 7 of differentiation stage, half of
exhausted medium was replaced by the fresh medium containing
the same concentration of cytokines. Cell numbers were deter-
mined by the trypan blue (Gibco) dye exclusion method and they
were reported by considering the number of expanded cells
cultivated in the differentiation stage.
2.2. Cell characterization
(i) Inorder toassess thedegreeofmegakaryocyticdifferentiation,
CD41 (Mk lineage cells) expressionwas analyzed by ﬂow cytometry
(FACSCalibur, BD) using an anti-CD41 antibody (Biolegend). CD34
and CD33 expression was also determined using appropriate
antibodies and isotype controls. (ii) Mk ploidy was determined by
double-staining technique with ﬂow cytometry (FACSCalibur, BD)
andusing CellQuest Pro software (BD) bychoosing CD41+ events as a
respected gate [13]. Brieﬂy, the cell cultures incubated 15min with
anti-CD41 antigen (Biolegend) and then ﬁxed by 70% cold ethanol
(4 C). Cells were re-suspended in a staining solution containing
propidium iodide (50mg/mL; Sigma), sodiumcitrate (4mM;Sigma),
RNaseA (0.1mg/mL; Sigma), TritonX-100 (0.1%; Sigma) inpH7.8 1h
before performing the ﬂow cytometry.
2.3. Electron microscopy
(i) For scanning electron microscopy imaging, cell population
were ﬁrst ﬁxed in a solution of glutaraldehyde (Sigma) 1.5% (v/v) in
PBS (Gibco), then post-ﬁxed in a solution of osmium tetroxide
(0.05%; Sigma) in PBS (Gibco); both for 30min at room temperature.
Cellswere then dehydrated by gradually increase of ethanol (Sigma)
concentration (50%, 75% and 100% in distilled water). Finally, cell
populationswere coatedwithgold andobservedusing scanelectron
microscope(HitachiS2400). (ii) Inordertoobserve internalstructure
of Mks by transmission electronmicroscopy (TEM), culture-derived
cells were ﬁxed in a solution containing 2% paraformaldehyde
(Sigma) and2.5%glutaraldehyde (Sigma) in0.1Msodiumcacodylate
buffer (Sigma) (pH 7.4) for 1h at room temperature (22 C). After
rinsing with cacodylate buffer (Sigma), cells were post-ﬁxed with a
1% osmium tetroxide (Sigma) in 0.1M cacodylate buffer (Sigma) for
1h at room temperature. Cells were then ﬁxed with uranyl acetate
(Sigma) (0.5%) in citrate–acetate acid buffer (pH: 5–6) and
dehydrated by graduate increasing ethanol (Sigma) concentration
(50%, 75% and 100% in distilledwater). Finally, cell populationswere
embedded in Epon (Sigma), cut and Mks ultrastructure observed
with TEM apparatus (Hitachi 8100).
2.4. Statistical analysis
Results are presented as a mean standard error of mean
(SEM). Results were statistically analyzed using two-sided
non-paired Student's t-test by Microsoft Excel and considered
signiﬁcant when p<0.05.
3. Results and discussion
3.1. Impact of the proliferation extent of CD34+ cells onmegakaryocytic
differentiation of UCB CD34+-enriched cells
CD34+-enriched cells from UCB were expanded using a
previously optimized protocol [12] and differentiated toward Mk
lineage using a simple protocol containing only two cytokines
(TPO and IL-3). Expanded cells were also differentiated, as a
control, using the same protocol but without any supplemented
cytokines. The effect of addition of TPO and IL-3 on Mk
differentiation is illustrated in Fig. 1.
Efﬁciency yield of the whole process (EY) was determined
according to Eq. (1). Therefore, EY is a measure on how many
megakaryocytic cells can be produced from each initial single UCB
CD34+-enriched cell seeded to the expansion stage.
EY ¼ number of CD41
þcells ðat the endof differentiation stageÞ
number of CD34þcellsðseeded to the expansion stageÞ
(1)
The result presented in Fig. 1 demonstrated that the higher
percentage of CD41+ cells can obtained by increasing concentration
of TPO (p<0.04 for 100ng/mL compared to 30ng/mL). However,
increasing TPO concentration alone, from 30 to 100ng/mL, was not
enough to stimulate a simultaneous cell differentiation and
proliferation at high levels. The combination of TPO (100ng/mL)
and IL-3 (10ng/mL) lead to a signiﬁcant increase in EY and %CD41,
when compared to the control (p<0.05 for both parameter). The
introduction of IL-3 at a low concentration (10ng/mL), together
with TPO (100ng/mL), allowed to increase 3.2 times the total EY of
the process (p<0.05), though such increase in EY was obtained on
the expense of CD41 purity, corresponding to a slight, but
statistically signiﬁcant 10% decrease (p<0.05) in %CD41. Consider-
ing these results, the following experiments were performed using
TPO (100ng/mL) and IL-3 (10ng/mL) in the differentiation stage.
In the present study we were able to quantitatively determine
the relation between the extent of proliferation of CD34+ cells,
[(Fig._1)TD$FIG]
Fig.1. Effect of different TPO concentrations and combinationwith IL-3, used in the
differentiation stage, on EY and %CD41. (* – p<0.04 and  – p<0.05).
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assessed as fold increase in CD34+ cells (FI-CD34+) and ﬁnal Mk
production (EY and %CD41 in Fig. 2A and C, respectively). FI-CD34+
was calculated according to Eq. (2).
FICD34þ ¼ number of CD34
þcells ðat the endof expansion stageÞ
number of CD34þ cells ðseeded to the expansion stageÞ
(2)
Cell populations were grouped in order to individualized
distinct relations between EY and FI-CD34+. The criteria used for
such population grouping were to minimize SEMs associated to
both EY and FI-CD34+, but more importantly to obtain statistically
signiﬁcant differences between such groups (p<0.05). Consider-
ing these criteria, the best possible grouping (G1, G2 and G3) was
represented in Fig. 2A and C. FI-CD34+ obtained for G1, G2 and G3
were 6.51.0, 172.0 and 427.1, respectively, corresponding to
0.850.11106, 2.10.16106 and 4.80.77106 CD34+ cells at
the end of the expansion stage. The G1 group with the lowest
FI-CD34+ has the lowest EY of 7.31.5 (0.980.21106 CD41+
cells at end of differentiation stage).
Comparison between G3 and G2 results points out that despite
thehigherFI-CD34+obtained forG3, a lowerEY(224.7vs.493.7;
p<0.05), a lower %CD41 (194.6% vs. 363.8%; p<0.05) and a
lower number of CD41+ cells (2.70.63106 vs. 6.0 0.67106;
p<0.05) were obtained, by the end of the differentiation, for G3
when compared to G2. Therefore, these results demonstrated that
an over-expansion of CD34+ cells led to a loss of Mk commitment
potential of the expanded cells. This observation is highlighted
when two populations of CD34+-enriched cells from the same UCB
were cultured; one of this populations was expanded with a
FI-CD34+ in the range of G2 (FI-CD34+:15.1) and another one in the
range of G3 (FI-CD34+:60). The ﬁrst experiment resulted in EYof 67
with 25% CD41+ cells though the second experiment resulted in a
lower EY and %CD41 (38 and 5.9%, respectively). Considering that
the FI-CD34+ is related with cell population doublings, in an
idealized cell population, a FI-CD34+ of 16 and64would correspond
to 4 and 6 cell population doublings, respectively. Different factors
can contribute to the loss of Mk differentiation potential for G3,
namely cell commitment toward the granulocytic and monocytic
[(Fig._2)TD$FIG]
Fig. 2. Effect of UCB CD34+-enriched cell's expansion stage, co-cultured with a feeder layer, on megakaryocytic differentiation: EY (A) and %CD41 (C) were evaluated with
respect to FI-CD34+ (EYand FI-CD34+were signiﬁcantly different among all groups, p<0.05). EY (B) and %CD41 (D) were evaluatedwith respect to the expansion duration (no
signiﬁcant differences between groups, p > 0.3). %CD41 was signiﬁcantly different between G2 and either G1 or G3, p<0.05), n4 for each group.
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lineage (24.0 4.3% CD14+ cells) [12], or neutrophil lineages
(64.012.1% HLA-DR++ CD117++) [14].
As a control, UCB CD34+-enriched cells were expanded in the
same culture conditions, but in absence of feeder layer; regardless
the different conditions tested, both FI-CD34+ and EY were
maintained at low levels (2.70.91 and 7.01.2, respectively;
n =3). It has been previously reported that FI-CD34+ was consis-
tently lower in the absence of feeder [12,15]. Therefore, this result
highlighted the positive effect of presence of feeder layer, in the
expansion stage, when targeting an efﬁcient Mk differentiation.
[(Fig._4)TD$FIG]
Fig. 4. Microscopy imaging: representative scanning electron microscopy images of human peripheral blood-derived platelets (left) and ex-vivo generated UCB-derived
platelet-like particles (right) (A), transmission electron microscopy (TEM) images of culture-derived Mk. The nucleus (N), demarcation membrane (dm) and a-granules (G)
are indicated in the image (B). Morphology of culture-derived cells by inverted microscopy (C). All images were drawn from G2 group.
[(Fig._3)TD$FIG]
Fig. 3. Phenotypic characterization of the UCB CD34+-enriched population; %CD33 (A), %CD 34 (B) and %CD41 (C) of each group at the start of expansion (start), the end of
expansion (Exp.) and differentiation (Diff.) stages. Results presented as mean SEM (n4) and p<0.05 between * and .
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Boyer and colleagues have previously suggested a 5-day
expansion period as optimal for the increased production of
Mks from UCB CD34+ cells (>95% enriched) in a two-phase
protocol. However, using FI-CD34+ in the expansion stage as an
operational parameter, rather than the expansion duration, has
more advantages such as considering the intrinsic biological
variability of UCB samples and the impact of initial CD34+
enrichment. The current study thus demonstrated that by using
FI-CD34+, as a key parameter, we were able to determine the
effectiveness of megakaryocyte differentiation of UCB cells,
identifying different groups with statistical signiﬁcance (G1, G2
and G3 in Fig. 2A and C in terms of FI-CD34+, p<0.05). Indeed, such
identiﬁcation would not be statistically signiﬁcant if expansion
duration was used instead (Fig. 2B and D; p >0.3 between G1, G2
and G3 in terms of expansion duration).
In the current study, the initial population consisted of 1.5105
cellswith similar cell population compositions (Fig. 3). At the end of
the expansion, the total numbers of cells were 1.70.40106,
4.20.30106 and 209.1106 for G1, G2 and G3, respectively. In
the expansion stage, the reduction in %CD34 (from 90 to 65% for G1,
from83%to51%forG2and from77%to36% forG3)wasaccompanied
byan increase in%CD33 (earlymyeloidcells), from56% to83% forG1,
from 52% to 91% for G2 and from 53% to 92% for G3.
A signiﬁcant decrease in %CD34 was observed during the
differentiation stage (from 65% to 2.9% for G1, 51–2.5% for G2 and
36–5% for G3, Fig. 3A and B). Such decrease in %CD34 was
concomitant to an increase in %CD41 indicating differentiation
toward Mk lineage. Comparing with the expansion stage, %CD41
increased during differentiation stage from13% to 19% for G1,while
for G2 raised from 13% to 35%, but only from 17% to 19% for G3
(Fig. 3C). Over differentiation stage, the total number of cells
increased about 3.7 folds for G1 (corresponding to 6.31.0106
total cells), and 4.4 folds for G2 (corresponding to 194.2106
total cells), but only about 1.3 for G3 (corresponding to
2613106 total cells).
3.2. Characterization of cultured-derived Mks and platelets-like
particles
Scanning electron microscopy analysis showed similar mor-
phology of culture-derived platelet-like particles and human
PB-derived platelets (Fig. 4A, right and left, respectively),
demonstrating the ability of the current protocol to support the
in vitro production of platelet-like particles. Likewise, transmis-
sion electron microscopy (TEM) analysis of culture-derived Mk
(Fig. 4B) showed normal features of a mature Mks with
demarcation membrane (dm) system, nucleus (N) and a-granules
characteristic of such mature Mk. Electron microscopy (SEM and
TEM) imaging was performed on 3 different populations from G2
and for each culture, platelet-like particles (similar to the Fig. 4A)
was identiﬁed in more than 10 microscopy images.
Ploidy analysis (Fig. 5A) revealed that about 18% of culture-
derived Mks have higher ploidy (>4N). Moreover, forward (FCS)
and side scatter (SCC) properties of such population are higher
compared to the CD41+ cells with 2N and 4N DNA content
(Fig. 5B). Mks generated from UCB, compared to human PB, were
described to be smaller and have less ploidy; however, as reported
previously [13] and conﬁrmed in the current study, these are still
able to produce platelets-like particles.
4. Conclusions
The current study presents a two-stage protocol aiming at
effective megakaryocytic differentiation of UCB CD34+-enriched
cells. The results identiﬁed distinct individual groups which
elucidate the relation between FI-CD34+ and efﬁciency of Mk
production. This information is valuable to balance the proliferation
and differentiationpotential of CD34+ cells, when targeting efﬁcient
Mk production. The underlying phenomena for such balance should
be actually based in cell population doublings, but FI-CD34+ is a
tangible parameter easier to quantify. Several studies have reported
production of Mk cells and platelets from HSC/HCP. For example,
using UCB progenitors, a perfusion system was used to produce
enough number of platelets in vitro for clinical transfusion (300–
600109) [16].However, thedrawbackofaforementionedworkwas
most of culture-derived platelets were activated in the absence of
any agonists. Another study reported producing 44 8.1Mks/input
HSC/HPC using humanmPB cells through a complex 3-step culture;
includes a cocktail comprised by 17 different cytokines and changes
inpHandO2 tensionduringexperiment [17].However, byusingonly
twocytokines(TPOandIL-3), in thedifferentiationstage,oursimpler
differentiation protocol was able to produce 487.7Mks/input
[(Fig._5)TD$FIG]
Fig. 5. Ploidy analysis of culture-derived Mks (A), forward (FSC) and side (SCC) scatter properties of CD41+ cells with 2N, 4N and >4N DNA content (light-yellow) (B).
Background scatters (dark-grey) belong to all CD41+ cell population. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to thewebversion
of this article.)
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CD34+ cells using a 172.5 FI-CD34+ and beneﬁts from using UCB
progenitors which are largely available and usually discarded after
delivery involving a non-invasive collection procedure. This work
quantitatively demonstrates that the FI-CD34+, rather than expan-
sion duration, can be used as a key parameter to maximize Mk cell
generation from CD34+-enriched cells. When adapted to fully
deﬁned, GMP-compliant culture reagents and conditions, this
protocol has the potential to impact cellular therapies within the
hemato-oncological ﬁeld.
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